Klinikum Chemnitz gGmbH
Chemnitz, Germany
26 recruiting
Showing 1–20 of 38 trials
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Relapsed Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd.900 enrolled68 locationsNCT06285318
Recruiting
Phase 3
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
GlioblastomaGBMRecurrent Glioblastoma
CarThera560 enrolled51 locationsNCT05902169
Recruiting
Phase 3
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Triple-Negative Breast Cancer
West German Study Group348 enrolled42 locationsNCT06081244
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC380 enrolled80 locationsNCT07230691
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled291 locationsNCT06252649
Recruiting
Phase 2
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company65 enrolled40 locationsNCT07015242
Recruiting
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
Non-small Cell Lung Cancer
Regeneron Pharmaceuticals500 enrolled49 locationsNCT05363319
Recruiting
Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer714 enrolled372 locationsNCT06758401
Recruiting
Phase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
Hoffmann-La Roche250 enrolled59 locationsNCT06847542
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled366 locationsNCT05253651
Recruiting
Phase 3
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled413 locationsNCT07222566
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences695 enrolled218 locationsNCT06801834
Recruiting
Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Gastric CancerGastroesophageal-junction Cancer
Daiichi Sankyo726 enrolled250 locationsNCT06731478
Recruiting
Phase 2Phase 3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Non-small Cell Lung Cancer
BioNTech SE1,260 enrolled261 locationsNCT06712316
Recruiting
Phase 1Phase 2
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics Biotechnologies GmbH400 enrolled29 locationsNCT05958121
Recruiting
Phase 3
A Study of Daratumumab
Multiple Myeloma
Janssen Research & Development, LLC500 enrolled92 locationsNCT05438043
Recruiting
Phase 3
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled179 locationsNCT05232916
Recruiting
Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection
VEXAS Syndrome
Technische Universität Dresden500 enrolled17 locationsNCT06377462
Recruiting
Phase 2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Primary Biliary CholangitisPBC
Mirum Pharmaceuticals, Inc.260 enrolled130 locationsNCT05050136
Recruiting
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
HER2-positive Advanced Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company257 enrolled76 locationsNCT05993234